Mizagliflozin, also known by its synonyms DSP-3235 free base, KGA-3235 free base, and GSK-1614235 free base, is a highly potent and orally active compound primarily recognized as a selective inhibitor of SGLT1 (sodium-glucose cotransporter 1). Its inhibitory constant (Kᵢ) against human SGLT1 is 27 nM, showcasing a remarkable selectivity profile with 303-fold greater potency for SGLT1 compared to SGLT2. This selectivity makes it a promising antidiabetic agent, as it can effectively modify postprandial blood glucose excursion, helping to manage blood sugar levels after meals. Beyond its antidiabetic properties, Mizagliflozin has also demonstrated potential in alleviating chronic constipation, exhibiting a laxative effect in animal models.
- Potent and selective SGLT1 inhibitor
- Orally active compound
- Modifies postprandial blood glucose excursion
- Potential in ameliorating chronic constipation